AZT Share Price Performance
NOK 20.80
-8.30 (-28.52%)
25.7% undervalued intrinsic discount
NOK 28.00
Fair Value
Price NOK 20.80
AnalystConsensusTarget NOK 28.00
Fair ValueNOK 28.00
Share Pricen/a
Analysis Article • Aug 18
ArcticZymes Technologies ASA Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
AZT Community Narratives
AN
Fair Value
·Fair Value NOK 28 25.7% undervalued intrinsic discount
Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies
ArcticZymes sells enzymes that help other companies make and test new medicines, and it’s seeing growing demand as gene and cell therapies move from labs toward larger-scale production. The catch is that growth still depends on a small number of big customers and many partners are only testing the products, so results can swing if adoption takes longer than hoped.Read more
AN
NOK 28
25.7% undervalued intrinsic discount
Fair Value
Revenue
14.71% p.a.
Profit Margin
27.44%
Future PE
32.59x
Price in 2029
NOK 33.93
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
AZT: New RNA Patent Will Support Future Biomanufacturing Upside
Fair Value: NOK 28 25.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ArcticZymes Technologies ASA Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 05, 2026
- 0.30
- 95.42%
- 11.54%
- 0%
About AZT
- Founded
- 1990
- Employees
- 51
- CEO
- WebsiteView website
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools market, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Recent AZT News & Updates
Narrative Update • Jul 29
